SGLT2i treatment in DKD patients prevented increases in urinary levels of podocyte-specific molecules (podocin, podocalyxin, synaptopodin), indicating a protective effect on podocyte integrity. This evidence concerns the gene NPHS2 and diabetic kidney disease.